Barclays Reiterates Overweight Rating on Quest Diagnostics Incorporated (DGX)

Market Context

Quest Diagnostics Incorporated operates in the Healthcare sector. The stock currently trades at $227.86 with a market capitalization of $20.3B. The stock has gained 21.9% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Quest Diagnostics Incorporated.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Quest Diagnostics Incorporated

Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 24, 2026	Barclays	Overweight	N/A
Jul 24, 2026	Baird	Neutral	N/A
Jul 24, 2026	Truist Securities	Hold	N/A
Jul 24, 2026	Mizuho	Outperform	N/A
Jul 24, 2026	UBS	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View DGX Stock Page